Acurx PharmaceuticalsACXP
ACXP
About: Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Employees: 4
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.23% less ownership
Funds ownership: 7.91% [Q2] → 7.68% (-0.23%) [Q3]
16% less capital invested
Capital invested by funds: $2.81M [Q2] → $2.37M (-$441K) [Q3]
16% less funds holding
Funds holding: 25 [Q2] → 21 (-4) [Q3]
32% less call options, than puts
Call options by funds: $17K | Put options by funds: $25K
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$12
1,355%
upside
Avg. target
$12
1,355%
upside
High target
$12
1,355%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Ed Arce 54% 1-year accuracy 79 / 146 met price target | 1,355%upside $12 | Buy Reiterated | 10 Dec 2024 |
Financial journalist opinion
Based on 3 articles about ACXP published over the past 30 days
Neutral
Accesswire
1 week ago
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ:ACXP), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference, which will take place January 28 to January 30, 2025 at the Borgata Hotel, Atlantic City, New Jersey.
Neutral
PRNewsWire
1 week ago
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications
Following the previously announced successful End of Phase 2 Meeting achieving agreement with FDA on non-clinical and clinical Phase 3-readiness, Acurx has now also received written positive feedback from FDA regarding acceptability of our CMC (Chemistry Manufacturing and Controls) plan and data package proposed to support the Phase 3 clinical program Acurx has initiated the Scientific Advice procedure with the European Medicines Agency (EMA) to discuss the readiness for initiation of the Phase 3 clinical program in the European Union (EU). Acurx has been notified that we should expect to receive the final written advice letter in the coming few weeks Acurx is also in the process of discussing the pediatric development plans for ibezapolstat in C.
Positive
Zacks Investment Research
3 weeks ago
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now
Acurx Pharmaceuticals (ACXP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Neutral
CNBC
1 month ago
Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook
The board of Acurx Pharmaceuticals has approved the purchase of up to $1 million in bitcoin to hold as a treasury reserve asset.
Neutral
PRNewsWire
1 month ago
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset
STATEN ISLAND, N.Y. , Nov. 20, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin to hold as a treasury reserve asset.
Neutral
PRNewsWire
1 month ago
Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update
Acurx is proud to sponsor this inaugural Scientific Symposium of the Peggy Lillis Foundation (PLF) for C. Diff Education & Advocacy An update of ibezapolstat Ph2b clinical and microbiome results was presented Preparation continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C.
Neutral
Seeking Alpha
1 month ago
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Robert Shawah - Co-Founder & CFO David Luci - Co-Founder, President, CEO, Corporate Secretary & Director Conference Call Participants Thomas Yip - H.C. Wainwright John Stinson - Private Investor Operator Greetings, and welcome to the Acurx Pharmaceuticals, Inc. Third Quarter 2024 Results and Business Update Conference Call.
Neutral
PRNewsWire
1 month ago
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update
STATEN ISLAND, N.Y. , Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2024.
Positive
Seeking Alpha
2 months ago
Acurx Ready To Expand Pipeline With Anthrax Treatment
Acurx Pharmaceuticals is undervalued, with promising market potential for its lead antibiotic, ibezapolstat, targeting C. difficile infections, a billion-dollar opportunity. Ibezapolstat's Phase 2 trials showed a 96% cure rate, positioning it as a potential game-changer with no preexisting resistance and minimal microbiome impact. The company's second asset showed activity against drug-resistant anthrax, making it a possible candidate for government funding.
Neutral
PRNewsWire
2 months ago
Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference
The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C. difficile Infection (CDI) Ibezapolstat treatment of patients with CDI is associated with the restoration of beneficial bacterial classes in the gut Preparation continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C.
Charts implemented using Lightweight Charts™